Gonadorelin

Dosing from the Literature

Published for testosterone support: pulse-pump doses every 60–120 minutes for hormone deficiency. Not published: a trial of the twice-daily shots clinics use on TRT.

What It Is

Gonadorelin is synthetic gonadotropin-releasing hormone (GnRH), also known as luteinizing hormone-releasing hormone (LHRH). GnRH is a 10-amino-acid peptide (pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) produced by neurons of the preoptic area of the hypothalamus. It is the master signal of the reproductive endocrine axis — released in discrete pulses into the hypothalamic-pituitary portal vasculature, it travels to the anterior pituitary, where it binds the GnRH receptor (GnRHR) on gonadotroph cells to trigger synthesis and release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH and FSH in turn act at the gonads to drive gametogenesis, steroidogenesis, and ovulation.

GnRH was isolated and structurally characterized in 1971 by Andrew Schally and Roger Guillemin (working independently). The isolation required processing hundreds of thousands of animal hypothalami to yield enough peptide for sequencing — one of the most arduous biochemistry projects of the 20th century, and one for which Schally and Guillemin shared the 1977 Nobel Prize in Physiology or Medicine. The synthetic peptide was subsequently manufactured and made available as a pharmaceutical.

In the United States, gonadorelin has had multiple historical FDA approvals. Factrel (gonadorelin hydrochloride, Wyeth Ayerst) was approved as a single-dose diagnostic agent for assessing pituitary gonadotroph function; it was later discontinued commercially. Lutrepulse / Lutrelef (gonadorelin acetate, Ferring) was approved as a pulsatile infusion-pump drug for induction of puberty and ovulation in hypogonadotropic hypogonadism; it too has been discontinued in the U.S. market. Modern U.S. clinical use of gonadorelin — predominantly as an adjunct to testosterone replacement therapy (TRT) for fertility preservation — is almost entirely through 503A compounding pharmacies on off-label prescription.

The modern community surge in gonadorelin use was driven by regulatory circumstance rather than by superior clinical evidence. In 2020, the FDA reclassified human chorionic gonadotropin (HCG) as a biologic, which removed it from 503A compounding pharmacy access under the updated rules. HCG had been the standard TRT adjunct for preserving testicular size, intratesticular testosterone production, and spermatogenesis — but with HCG no longer compoundable, telehealth TRT clinics and men's-health practitioners adopted gonadorelin as a substitute. Gonadorelin acts one step upstream of HCG — at the pituitary rather than the testicle — which raises legitimate clinical questions about whether intermittent SubQ gonadorelin reliably overcomes the pituitary suppression induced by exogenous testosterone. No published study has answered them.

Mechanism of Action

• GnRH receptor (GnRHR) agonism at the anterior pituitary — Gonadorelin has the same structure as natural GnRH and acts on the anterior pituitary to release the gonadotropins LH and FSH (Factrel label; Schally et al., 1971). This is the central pharmacological action.
• LH → testosterone cascade — LH stimulates the Leydig cells of the testes to make testosterone, and high testosterone inside the testes is critical for sperm production. Testosterone given from outside suppresses GnRH and LH through negative feedback, and with them the testes' own testosterone, which is why the LH signal matters on TRT even though blood testosterone is supplied (Ramasamy et al., 2015).
• FSH → spermatogenesis — FSH acts on the Sertoli cells, which support sperm production; in men with hypogonadotropic hypogonadism on GnRH therapy, this FSH–Sertoli cell side normalized less uniformly than the LH–testosterone side (Pitteloud et al., 2002).
• Continuous vs pulsatile paradox (the central mechanism) — In rhesus monkeys with hypothalamic lesions, GnRH pulses once an hour, their natural frequency, restored gonadotropin secretion while a constant infusion did not; the pattern of delivery, not the amount, decided the response, and switching from pulses to a constant infusion desensitized gonadotropin release. Belchetz 1978 (Science, PMID 100883) is the foundational paper demonstrating this paradox. Long-acting GnRH agonists given as depots, such as leuprolide, goserelin and triptorelin, use this desensitization to shut the reproductive axis down, in prostate cancer among other diseases (Conn & Crowley, 1994). Hoffman & Crowley 1982 (NEJM, PMID 6813732) showed pulsatile GnRH induces puberty in hypogonadotropic men.
• Natural GnRH in pulses stimulates; long-acting analogs suppress — Natural-sequence GnRH given in pulses by portable pump restores reproduction in men and women whose own GnRH secretion fails, while long-acting GnRH agonists given as depots shut the axis down; that is why the natural peptide, not a long-acting analog, is the one used to stimulate (Conn & Crowley, 1994).
• Practical translation for TRT — Twice-daily SubQ gonadorelin in clinic protocols gives two pulses a day; in the pump studies, pulses came every 90 minutes in men (Zhang et al., 2019) and every 60–90 minutes in most cycles in women (Filicori et al., 1994). Whether two pulses a day keep the pituitary responding during TRT-induced suppression has not been tested in a published trial.

What the Research Shows

• Foundational pharmacology — continuous vs pulsatile (Belchetz 1978, PMID 100883) — Belchetz PE et al. Hypophysial responses to continuous and intermittent delivery of hypothalamic (brain's hormonal control center) gonadotropin-releasing hormone. Science 1978;202(4368):631-633. Demonstrated in ovariectomized rhesus monkeys that pulsatile GnRH maintains LH / FSH output while continuous GnRH paradoxically suppresses it. The foundational paper for the entire GnRH pharmacology.
• Puberty induction in hypogonadotropic men (Hoffman & Crowley 1982, PMID 6813732) — Hoffman AR, Crowley WF. Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone. N Engl J Med 1982;307(20):1237-1241. Pulsatile SubQ GnRH restored LH / FSH, testosterone, and spermatogenesis in men with isolated hypogonadotropic hypogonadism.
• Diagnostic efficacy — The former FDA indication for Factrel: a single 100 mcg injection, under the skin or into a vein, to test the pituitary's gonadotropes. In healthy adults it raised LH, peaking at a mean 27–34 minutes in men; patients with pituitary or hypothalamic disease often had subnormal or no response (33 of 44 with Kallmann's syndrome), but the single-injection test did not tell the two apart and does not measure pituitary reserve (Factrel label).
• Pulsatile pump protocols for hypogonadotropic hypogonadism — In 76 men with idiopathic hypogonadotropic hypogonadism given pulses under the skin for 12–24 months, starting at 5–25 ng/kg per pulse and titrated to normal adult testosterone, LH and testosterone normalized in 97% and 93%; the men with some earlier puberty all produced sperm, while 18% of those with none stayed azoospermic (Pitteloud et al., 2002). In 292 women with anovulation, pulses of 1.25–20 mcg into a vein every 30–120 minutes brought ovulation in 75% of 600 cycles (Filicori et al., 1994).
• HCG comparison — HCG directly mimics LH at the testicular level and has decades of clinical evidence for maintaining testicular function on TRT. Gonadorelin works upstream at the pituitary level, which is already suppressed by exogenous testosterone. This raises legitimate questions about whether intermittent SubQ gonadorelin can reliably overcome TRT-induced HPG suppression. No head-to-head RCT.
• Fertility preservation debate — No published study has tested whether intermittent SubQ gonadorelin, without a pump, preserves sperm production during TRT. HCG has studies in men on testosterone (Ramasamy et al., 2015), and the pump has trials in men with hypogonadotropic hypogonadism (Pitteloud et al., 2002).

Human Data

Human data for gonadorelin span decades of clinical use in endocrinology, with the strongest evidence for diagnostic and pulsatile-pump applications and thinner evidence for the modern TRT adjunct role.

• Pulsatile GnRH for hypogonadotropic hypogonadism — In six men with idiopathic hypogonadotropic hypogonadism, GnRH pulses under the skin by portable pump raised testosterone from a mean 77 to 520 ng/dL within a month; testes grew in four and three produced sperm by 43 weeks (Hoffman & Crowley 1982, NEJM). In 76 men, LH and testosterone normalized in 97% and 93% (Pitteloud et al., 2002). In a nonrandomized comparison, 9 of 10 men on a pump (10 mcg every 90 minutes) produced sperm, at a median 6 months against 14 months for 18 men on hCG/HMG injections (Zhang et al., 2019).
• Pulsatile GnRH for ovulation induction — Pulsatile gonadorelin was used for ovulation induction in women with hypothalamic amenorrhea — the original indication for Lutrepulse / Lutrelef. Largely displaced by recombinant gonadotropins in modern ART practice, but still used in some reproductive centers.
• Diagnostic testing (Factrel historical indication) — The label's test: LH drawn 15 minutes before and just before 100 mcg under the skin or into a vein, then at 15, 30, 45, 60 and 120 minutes. A normal response shows working pituitary gonadotropes; in the label's studies the single-injection test did not tell pituitary from hypothalamic causes apart (Factrel label).
• Telehealth TRT real-world experience (post-2020) — Since March 2020, when HCG became a licensed biologic that, under FDA's notice to compounders, pharmacies can no longer compound, clinic protocols have described compounded gonadorelin, 100–200 mcg SubQ twice daily, as an HCG alternative. No study of its outcomes in men on testosterone therapy has been published.
• Pediatric hypogonadism — Long-term pulsatile-pump gonadorelin has been used in adolescents with hypogonadotropic hypogonadism for puberty induction, with good safety and efficacy in specialty centers.

Reconstitution & Storage

Compounding pharmacies list gonadorelin as a ready-mixed solution (1 mg/mL in a 5 mL vial) or as lyophilized powder in multi-dose vials of 1 mg, 2 mg, 3 mg or 5 mg, with BAC water supplied separately.

• Reconstitution — Online reconstitution guides describe adding bacteriostatic water slowly down the inside wall of the vial, then swirling gently rather than shaking. The discontinued Factrel label mixed its 100 mcg vial with 1 mL and its 500 mcg vial with 2 mL of the supplied diluent, immediately before use (Factrel label).
• Storage — Compounding pharmacy listings give refrigeration at 2–8°C, or room temperature (20–25°C) for some products, away from light, with a beyond-use date on the label. The discontinued Factrel powder was stored at room temperature and, once mixed, used within a day (Factrel label).
• Timing — Clinic protocols describe the twice-daily doses as morning and evening, roughly 12 hours apart.
• Inspection — The discontinued Factrel label called for checking the solution for particles and discoloration before injection (Factrel label).

→ Calculator — vial-to-syringe math

Side Effects & Risks

• Injection-site reactions — Swelling at the injection site, sometimes with pain and itching, after injection under the skin, and local or generalized rash after long-term use (Factrel label). On a pump, some of 10 men had red hardening at the needle site and one a small abscess (Zhang et al., 2019).
• Headache — Headache and light-headedness are among the systemic effects reported rarely after a 100 mcg dose (Factrel label).
• Flushing — Also among the rare systemic effects (Factrel label).
• Nausea — Nausea and abdominal discomfort, also among the rare systemic effects (Factrel label).
• Hypersensitivity reactions — Rare hypersensitivity reactions (bronchospasm, fast heartbeat, flushing, hives, hardening at the injection site) and anaphylactic reactions after repeated doses, none reported after a single 100 mcg dose; antibodies rarely after long-term large doses (Factrel label).
• Pituitary desensitization (the key pharmacologic risk) — Continuous GnRH desensitized gonadotropin release in monkeys (Belchetz et al., 1978), and the Factrel label warns that repetitive, high doses may cause luteolysis and inhibition of spermatogenesis (Factrel label).
• Insufficient efficacy — No published trial has tested whether the twice-daily injections prevent testicular shrinkage or keep sperm production going during TRT, which suppresses the pituitary signal they rely on (Ramasamy et al., 2015).
• Drug interactions — The Factrel label ran its test without drugs that directly affect the pituitary's gonadotropin secretion: androgens (testosterone among them), estrogens, progestins and glucocorticoids. It notes gonadotropins may be raised by spironolactone and levodopa and lowered by oral contraceptives and digoxin, and the response blunted by phenothiazines and dopamine antagonists, which raise prolactin (Factrel label). In theory, a depot GnRH agonist, which desensitizes the pituitary (Conn & Crowley, 1994), would blunt the response to gonadorelin.
• Pregnancy / lactation — The Factrel label placed it in pregnancy category B: no harm to the fetus in mice, rats and rabbits at up to 50 times the human dose, and no adequate studies in pregnant women; whether it passes into breast milk is not known (Factrel label). Pulsatile gonadorelin is also used to induce ovulation (Filicori et al., 1994).
• WADA status — banned (males) — Gonadorelin is on the 2026 WADA Prohibited List under S2.2 (LH-releasing peptides and GnRH analogs, prohibited in males).
• Sourcing — No approved gonadorelin product is sold in the U.S.: Drugs@FDA lists Factrel and Lutrepulse as discontinued, and 503A pharmacies compound it on prescription.

Bloodwork & Monitoring

No trial, label or guideline sets monitoring for gonadorelin used alongside testosterone therapy. A compounding pharmacy's guide to its use in men lists testosterone, LH, FSH and estradiol, and semen analysis when pregnancy is the goal; practitioner protocols describe checking LH and FSH at baseline, at 4–8 weeks and at 3 months. In a pump study of 76 men with idiopathic hypogonadotropic hypogonadism, the investigators measured LH, FSH, testosterone and inhibin B serially, with testicular volume and sperm counts (Pitteloud et al., 2002). Monitoring of testosterone therapy itself is on the testosterone page.

Commonly Stacked With

Stacking this? Read the receipt →

→ Calculator — vial-to-syringe math

Practical User Notes

• Injection timing — roughly 12 hours apart — Clinic protocols describe morning and evening doses for the twice-daily schedule.
• Natural GnRH, not a long-acting analog — Natural-sequence GnRH given in pulses restores reproductive function, while long-acting GnRH agonists given as depots suppress it (Conn & Crowley, 1994).
• GnRH agonists — Long-acting GnRH agonists (leuprolide, goserelin, triptorelin) desensitize the pituitary (Conn & Crowley, 1994); in theory, gonadorelin would then have little effect.
• Reconstituted with bacteriostatic water — Compounding pharmacies supply BAC water with their powder vials, and some supply a ready-mixed solution; their listings give refrigeration or room temperature, by product, and a beyond-use date.
• Allergic reactions — rare but real — The Factrel label reports rare hypersensitivity and anaphylactic reactions after repeated doses (Factrel label).
• Tested male athletes — not compatible — WADA S2.2 prohibition in males. Detection methods established.

Legal Status

Related Compounds

People researching Gonadorelin often also look at these:

Next Steps

References

1. Belchetz PE, Plant TM, Nakai Y, Keogh EJ, Knobil E. Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science. 1978;202(4368):631-633. PMID: 100883. (Foundational continuous-vs-pulsatile pharmacology paper.)
2. Hoffman AR, Crowley WF. Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone. N Engl J Med. 1982;307(20):1237-1241. PMID: 6813732. (Pivotal pulsatile GnRH clinical paper.)
3. Schally AV, Arimura A, Baba Y, Nair RM, Matsuo H, Redding TW, Debeljuk L. Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun. 1971;43(2):393-399. PMID: 4930860. (Schally GnRH isolation paper — Nobel Prize 1977.)
4. Matsuo H, Baba Y, Nair RM, Arimura A, Schally AV. Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun. 1971;43(6):1334-1339. PMID: 4936338. (GnRH primary structure.)
5. Santoro N, Filicori M, Crowley WF. Hypogonadotropic disorders in men and women: diagnosis and therapy with pulsatile gonadotropin-releasing hormone. Endocr Rev. 1986;7(1):11-23. PMID: 3082615. (Pulsatile GnRH therapy review.)
6. Crowley WF, McArthur JW. Simulation of the normal menstrual cycle in Kallman's syndrome by pulsatile administration of luteinizing hormone-releasing hormone. J Clin Endocrinol Metab. 1980;51(1):173-175. PMID: 6247361.
7. FDA. Factrel (gonadorelin hydrochloride) Prescribing Information. FDA.gov. Wyeth Ayerst (discontinued). (Historical FDA approval reference.)
8. FDA. Lutrepulse / Lutrelef (gonadorelin acetate) Prescribing Information. FDA.gov. Ferring (discontinued). (Historical FDA pulsatile-pump approval.)
9. Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogs. Annu Rev Med. 1994;45:391-405. PMID: 8198390. (Comprehensive GnRH pharmacology review.)
10. Filicori M, Flamigni C, Dellai P, Cognigni G, Michelacci L, Arnone R, Sambataro M, Falbo A. Treatment of anovulation with pulsatile gonadotropin-releasing hormone: prognostic factors and clinical results in 600 cycles. J Clin Endocrinol Metab. 1994;79(4):1215-1220. PMID: 7962297.
11. Seminara SB, Hayes FJ, Crowley WF Jr. Gonadotropin-releasing hormone deficiency in the human (idiopathic hypogonadotropic hypogonadism and Kallmann's syndrome): pathophysiological and genetic considerations. Endocr Rev. 1998;19(5):521-539. PMID: 9793755.
12. Pitteloud N, Hayes FJ, Dwyer A, Boepple PA, Lee H, Crowley WF Jr. Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2002;87(9):4128-4136. PMID: 12213860.
13. Rahnema CD, Lipshultz LI, Crosnoe LE, Kovac JR, Kim ED. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014;101(5):1271-1279. PMID: 24636400. (Context for modern HPG preservation strategies.)
14. Ramasamy R, Armstrong JM, Lipshultz LI. Preserving fertility in the hypogonadal patient: an update. Asian J Androl. 2015;17(2):197-200. PMID: 25337850. (TRT fertility preservation review — HCG context.)
15. WADA Prohibited List 2026. World Anti-Doping Agency. wada-ama.org. (Gonadorelin banned in males under S2.2.)
16. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (503A categories list), versions updated April 15, April 22 and May 14, 2026. fda.gov/media/94155/download. Read October 3, 2026. (Notice that 12 peptides would leave Category 2 because their nominations were withdrawn; their removal; GHK-Cu, except injectable, back in Category 1.)
17. Zhang L, Cai K, Wang Y, Ji W, Cheng Z, Chen G, Liao Z. The pulsatile gonadorelin pump induces earlier spermatogenesis than cyclical gonadotropin therapy in congenital hypogonadotropic hypogonadism men. Am J Mens Health. 2019;13(1):1557988318818280. PMID: 30569789.

Related Research

• TriptorelinGnRH Super-Agonist (Decapeptide)
• Enclomiphene CitrateSelective Estrogen Receptor Modulator (SERM)
• HCGGlycoprotein Gonadotropin (LH analog)
• KisspeptinEndogenous HPG Axis Master Regulator
• FDA TrackerPCAC voted on 7 of the 12 peptides on July 23–24, 2026; FDA plans a PCAC review of the other 5 before the end of February 2027.
• HMGMenotropins (Urinary FSH + LH Activity)